What changed in this filing

/stocks — the workspaceLOADING

Item 2. Unregistered Sales of Equity Securities

2022-11-14 compared with 2022-08-15 · 17 added, 21 removed, 2 unchanged (95% of the section changed)

Unregistered Sales of Equity Securities and Use of Proceeds

See the disclosure under Item 5 below, which is incorporated

herein by reference, for a description of the shares issuable under the sixth amendment to our Management Services Agreement with PAVmed

In addition, effective as of May 25, 2022, we issued 117,371 shares of our common stock to an entity designated by RDx, in satisfaction

of a $250,000 installment payment due under the asset purchase agreement dated February 25, 2022, between LucidDx Labs Inc.

(a wholly-owned

subsidiary of Lucid Diagnostics Inc.) and ResearchDx Inc.

(“RDx”), and unrelated third-party - referred to as “APA-RDx”.

See the Current Report on Form 8-K filed by us with the SEC on March 3, 2022, which is incorporated herein by reference, for a fuller

description of the APA-RDx and the installment payments thereunder.

The shares of our common stock are being offering pursuant to the

APA-RDx in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended, for the

sale of securities not involving a public offering.

October 14, 2021, we completed our initial public offering (“IPO”) of our common stock under an effective registration

statement on Form S-1 (SEC File No.

As of June 30, 2022, of the net proceeds of $64.4 million, approximately $31.7

million has been used, in a manner consistent with the use of proceeds set forth in the prospectus for our IPO, as follows:

approximately $3.9 million of net repayments due to PAVmed Inc.;

approximately $3.4 million for the purchase of our laboratory

equipment, software, and its operating expenses;

See the disclosure in “Liquidity and Capital Resources - Committed Equity Facility - March 28, 2022” under Item

2 above and in the Current Report on Form 8-K filed by us with the SEC on April 1, 2022, each of which is incorporated herein by reference,

for a description of the committed equity facility with Cantor and the shares issuable to Cantor thereunder.

addition, effective as of August 25, 2022, we issued 82,618 shares of our common stock to an entity designated by RDx, in satisfaction

of a $250,000 installment payment due under the asset purchase agreement dated February 25, 2022, between LucidDx Labs (our wholly-owned

subsidiary) and RDx, and unrelated third-party.

See the Current Report on Form 8-K filed by us with the SEC on March 3, 2022, which is

incorporated herein by reference, for a fuller description of the asset purchase agreement with RDx and the installment payments thereunder.

October 14, 2021, we completed our initial public offering (“IPO”) of our common stock under an effective registration statement

on Form S-1 (SEC File No.

As of September 30, 2022, of the net proceeds of $64.4 million, approximately $39.3 million has

been used, in a manner consistent with the use of proceeds set forth in the prospectus for our IPO, as follows:

approximately $5.3 million

of net repayments due to PAVmed;

approximately $4.7 million for the purchase of our laboratory equipment, software, and its operating

and $29.3 million of working capital expenditures.

None of the proceeds have been paid to any of our directors,

officers, 10% stockholders, or affiliates, other than as described above.

None of the proceeds have been paid to any of our directors, officers, 10%

stockholders, or affiliates, other than as described above.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 2. Unregistered Sales of Equity Securities